ABOUT US

MedAccess Board and Governance

Led by Professor Helen Rees, our Chair, the MedAccess board is responsible for our oversight and governance. Board members are drawn from the fields of public health, pharmaceuticals and finance.

Helen Rees

Board Chair
Helen is a global health leader who has dedicated her life to improving the health of people in low- and middle-income countries through her research and her contribution to global health policy.

Helen is a member of the Governance & Nominations Committee.
Helen Rees

Helen Rees

Board Chair

Helen Rees is a global health leader who has dedicated her life to improving the health of people in low- and middle-income countries through her research and her contribution to global health policy.

Professor Rees started her career as a family doctor in the UK before moving to South Africa to provide medical assistance to communities denied access during apartheid. In 1994, she founded the Wits Reproductive Health and HIV Institute (Wits RHI) to expand African-generated research into HIV, tuberculosis, sexually transmitted infections, reproductive health and vaccines. Professor Rees remains the Institute’s Executive Director.

Professor Rees chairs and is a member of several World Health Organization (WHO) committees and working groups, including the African Regional Immunization Technical Advisory Group and the WHO Emergency Committee on Polio. She served on the Board of Gavi and is a former chair of the Vaccine Alliance’s Programme and Policy Committee. Professor Rees is also the board chair of the South African Health Products Regulatory Authority.

Drawing on her leadership of Wits RHI and her expertise in global health governance, Professor Rees supported South Africa’s COVID-19 response through her role on the Ministerial Advisory Committee on COVID-19. She remains a member of the country’s Ministerial Advisory Committee on COVID-19 vaccines. In 2022 she received the platinum South African National Batho Pele Award for excellence in contribution to the South African COVID-19 response.

Professor Rees obtained her Medical Degree and Master’s in Social and Political Sciences from New Hall (now Murray Edwards) College at Cambridge. She is a graduate of Harvard Business School (HBS) having completed the HBS Senior Executive Programme.

Professor Rees is internationally renowned for her research into HIV and reproductive health, with more than 250 published academic papers to her name. She is an Honorary Professor at London School of Hygiene and Tropical Medicine, an Honorary Fellow of Murray Edwards College, University of Cambridge and has been awarded an Honorary Doctorate of Science (Medicine) by the University of London.

Professor Rees was awarded the OBE in 2001, the South African National Order of the Baobab in 2015 and the French National Order of Merit in 2022.

Professor Rees is Chair of the MedAccess Board of Directors and a member of the Nominations and Governance Committee.

Daniel Camus

Board Member
Daniel brings 25 years’ experience in international finance to his position as a MedAccess director, and joined the MedAccess Board in 2020 from his role as CFO of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Daniel is the Chair of the Audit & Finance Committee.
Daniel Camus

Daniel Camus

Board Member

Daniel brings 25 years’ experience in international finance to his position as a MedAccess director. During 11 years with the pharmaceutical group Aventis, he held a number of Chief Financial Officer roles, followed by 10 years as CFO at energy firm EDF. Daniel most recently served as CFO of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Daniel holds several other Non-Executive Director positions including with the Foundation for Innovative New Diagnostics (FIND), a Swiss-based non-profit healthcare organisation.

Diana Noble CBE

Board Member
Diana brings more than 30 years of experience in private equity, venture capital and international development. She combines Board responsibilities with chairing the MedAccess Investment Committee.

Diana is the Chair of the Investment Committee.
Diana Noble

Diana Noble CBE

Board Member

Diana brings over 30 years’ experience in private equity, venture capital and international development. She combines Board responsibilities with chairing the MedAccess Investment Committee.

Diana has held roles of CEO at CDC Group (now British International Investment), Executive Vice President Operations at the Clinton Health Access Initiative and Partner at Schroder Ventures (now Permira).

Dr. Egbe Osifo-Dawodu

Board Member
Egbe is a Partner at the Anadach Group, and a member of the UK Royal College of Physicians. Egbe’s 30 years of healthcare experience covers policy, provision and financing in Africa, Asia, Europe, and Latin America.

Egbe is the Chair of the People & Remuneration Committee, and a member of the Audit & Finance Committee and Governance & Nominations Committee.
Egbe Osifo-Dawodu

Dr. Egbe Osifo-Dawodu

Board Member

Egbe is a Partner at the Anadach Group, providing advisory services to a wide range of clients. She is a member of the UK Royal College of Physicians, with over 30 years’ healthcare experience covering policy, provision and financing in Africa, Asia, Europe, and Latin America.

Egbe has held various positions at the World Bank Group, working on public policy and investment transactions at the International Financial Corporation.

Holger Rothenbusch

Board Member
Holger is Managing Director & Head of the Infra and Climate Group at British International investment. Holger has spent 20 years in development finance in Latin America, Africa, Asia and Eastern Europe, working across emerging markets, sectors and products.

Holger is a member of the Investment Committee, the People & Remuneration Committee and the Governance & Nominations Committee.
Holger Rothenbusch

Holger Rothenbusch

Board Member

Holger is Managing Director & Head of the Infra and Climate Group at British International Investment (BII). He has spent over 20 years in development finance in Latin America, Africa, Asia and Eastern Europe, working across numerous emerging markets, sectors and products.

Prior to joining BII, Holger held several senior positions at the German Development Finance Institution, including building the Equity & Mezzanine Team. He started his career as a commercial banker with Deutsche Bank.

Willem Verhoofstad

Board Member
Willem has three decades’ experience in the pharmaceutical industry, holding leadership roles in product development, business development, strategic marketing, R&D strategy and portfolio management.

Willem is the Chair of the Governance & Nominations Committee, and a member of the Audit & Finance Committee and the People & Remuneration Committee.
Willem Verhoofstad

Willem Verhoofstad

Board Member

Willem is a former Senior Vice President at Roche Pharma in Switzerland.

He has over 34 years of experience in the pharmaceutical industry, culminating in various global leadership roles in product development, business development, strategic marketing, R&D strategy and portfolio management. His broad and deep experience covers a wide range of therapeutic areas and geographies.

Governance

The MedAccess Board and its committees are actively involved in the oversight of our organisation. Board members and committee members take a close interest in our success, providing guidance, scrutiny and approval on key activities.

The Board meets a minimum of four times per year to review MedAccess’ progress against its business plan targets and provide strategic input and guidance to the executive team.

Boardroom

Board Committees

The Board delegates specific tasks and decisions to four standing committees, which have Committee Chairs that report on their activities to the Board:

  • The Investment Committee screens and evaluates potential transactions and can provide approval on proposals up to $75 million. Membership of the Committee includes John Kelting, an independent member.
  • The Audit & Finance Committee provides oversight on MedAccess financial activities. Made up of a minimum of three members, this Committee reviews the organisation’s financial statements and provides guidance on risk and compliance.
  • The People & Remuneration Committee is responsible for approving and monitoring all aspects of remuneration and performance.
  • The Governance & Nominations Committee is responsible for the governance of MedAccess, including its Board and Committees, relationships with shareholders and filling vacancies in board positions.